Welcome to our dedicated page for Inventiva S.A. SEC filings (Ticker: IVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Inventiva S.A. filings document a foreign private issuer and ADR program tied to a clinical-stage biopharmaceutical company developing oral therapies for MASH. Form 6-K reports furnish press releases and meeting notices covering lanifibranor development, annual and preliminary financial results, R&D expense trends, cash resources, revenues, and financing activity.
The company's regulatory disclosures also cover governance and shareholder voting matters, annual general meeting materials, leadership and organizational changes, material agreements, capital-structure disclosures, and portfolio actions including the completed sale of odiparcil. These records connect Inventiva's drug-development focus with its reporting obligations as a France-based issuer listed through American depositary shares.
Schedule 13G filing: Great Point Partners, LLC ("Great Point"), along with Dr. Jeffrey R. Jay, M.D. and Ms. Lillian Nordahl, report a new 7.42 % passive stake in Inventiva S.A. (CUSIP F5R343107) as of 05 May 2025.
The group beneficially owns 10,576,827 ordinary shares, comprised of 7,243,495 shares held outright and warrants for 3,333,332 shares. The ownership calculation is based on 139,151,274 shares outstanding plus the warrant shares, as disclosed in Inventiva’s 6-K dated 05 May 2025.
- Great Point Partners, LLC is an investment adviser organised in Delaware and files as an IA/OO.
- Dr. Jay (Senior Managing Member) and Ms. Nordahl (Managing Director) each file as HC/IN with shared voting and dispositive power over the entire position; neither has sole power.
- The shares are held through two health-care–focused funds: Biomedical Value Fund, L.P. (4,853,356 shares + 2,166,666 warrants) and Biomedical Offshore Value Fund, Ltd. (2,390,139 shares + 1,166,666 warrants).
- The reporting persons expressly disclaim beneficial ownership except to the extent of their pecuniary interest.
No other material transactions, earnings data or strategic changes are disclosed. The filing is purely an ownership disclosure under Rule 13d-1(c), signalling that Great Point now exceeds the 5 % threshold and is required to report its passive investment in Inventiva.